Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample

Molecular Oncology

Volumn 10, Issue 4, 2016, Pages 566-574

  Rothwell, Dominic G ^a   Smith, Nigel ^a   Morris, Daniel ^a   Leong, Hui Sun ^a   Li, Yaoyong ^a,b   Hollebecque, Antoine ^a   Ayub, Mahmood ^a   Carter, Louise ^a   Antonello, Jenny ^a   Franklin, Lynsey ^a   Miller, Crispin ^a   Blackhall, Fiona ^b   Dive, Caroline ^a   Brady, Ged ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biomarker; Blood; CTC; CtDNA; NGS

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING FREE DNA; CIRCULATING TUMOR DNA; DNA; EDETIC ACID; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BLOOD; BLOOD CELL; BLOOD COLLECTION TUBE; BLOOD SAMPLING; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA ISOLATION; DNA SEQUENCE; EVALUATION STUDY; GENETIC ANALYSIS; GENOME; GENOTYPE; HUMAN; MUTATION RATE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; BLOOD STORAGE; FEMALE; GENETICS; MALE; METABOLISM; TIME FACTOR; TUMOR EMBOLISM;

BLOOD PRESERVATION; DNA, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; TIME FACTORS;

EID: 84961837282     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.11.006     Document Type: Article

References (27)

1. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26(19):3213-3221.
2. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004 Aug 19, 351(8):781-791.
3. de Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008 Oct 1, 14(19):6302-6309.
4. De Mattos-Arruda L., Cortes J., Santarpia L., Vivancos A., Tabernero J., Reis-Filho J.S., Seoane J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat. Rev. Clin. Oncol. 2013 Jul, 10(7):377-389.
5. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 2014 Feb 20, 32(6):579-586. Epub 2014 Jan 21. 10.1200/JCO.2012.45.2011.
6. Douillard J.Y., Ostoros G., Cobo M., Ciuleanu T., McCormack R., Webster A., et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br. J. Cancer 2014 Jan 7, 110(1):55-62.
7. Garcia-Murillas I., Schiavon G., Weigelt B., Ng C., Hrebien S., Cutts R.J., Cheang M., Osin P., Nerurkar A., Kozarewa I., Garrido J.A., Dowsett M., Reis-Filho J.S., Smith I.E., Turner N.C. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl Med. 2015 Aug 26, 7(302). 302ra133. 10.1126/scitranslmed.aab0021.
8. Gasch C., Bauernhofer T., Pichler M., Langer-Freitag S., Reeh M., Seifert A.M., et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 2013 Jan, 59(1):252-260. Epub 2012 Nov 7. 10.1373/clinchem.2012.188557.
9. George J., Lim J.S., Jang S.J., Cun Y., Ozretiä L., Kong G., Leenders F., Lu X., Fernández-Cuesta L., Bosco G., Müller C., Dahmen I., Jahchan N.S., Park K.S., Yang D., Karnezis A.N., Vaka D., Torres A., Wang M.S., Korbel J.O., Menon R., Chun S.M., Kim D., Wilkerson M., Hayes N., Engelmann D., Pützer B., Bos M., Michels S., Vlasic I., Seidel D., Pinther B., Schaub P., Becker C., Altmüller J., Yokota J., Kohno T., Iwakawa R., Tsuta K., Noguchi M., Muley T., Hoffmann H., Schnabel P.A., Petersen I., Chen Y., Soltermann A., Tischler V., Choi C.M., Kim Y.H., Massion P.P., Zou Y., Jovanovic D., Kontic M., Wright G.M., Russell P.A., Solomon B., Koch I., Lindner M., Muscarella L.A., la Torre A., Field J.K., Jakopovic M., Knezevic J., Castaños-Vélez E., Roz L., Pastorino U., Brustugun O.T., Lund-Iversen M., Thunnissen E., Köhler J., Schuler M., Botling J., Sandelin M., Sanchez-Cespedes M., Salvesen H.B., Achter V., Lang U., Bogus M., Schneider P.M., Zander T., Ansén S., Hallek M., Wolf J., Vingron M., Yatabe Y., Travis W.D., Nürnberg P., Reinhardt C., Perner S., Heukamp L., Büttner R., Haas S.A., Brambilla E., Peifer M., Sage J., Thomas R.K. Comprehensive genomic profiles of small cell lung cancer. Nature 2015 Aug 6, 524(7563):47-53.
10. Gormally E., Hainaut P., Caboux E., Airoldi L., Autrup H., Malaveille C., et al. Amount of DNA in plasma and cancer risk: a prospective study. Int. J. Cancer 2004 Sep 20, 111(5):746-749. Erratum in: Int J Cancer. 2006 Jul 15;119(2):476.
11. Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat. Res. 2007, 635(2-3):105-117.
12. Gužvić M., Braun B., Ganzer R., Burger M., Nerlich M., Winkler S., et al. Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes. Cancer Res. 2014, 74(24):7383-7394. Epub 2014 Oct 15. 10.1158/0008-5472.CAN-14-0934.
13. Heitzer E., Auer M., Gasch C., Pichler M., Ulz P., Hoffmann E.M., et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013, 73(10):2965-2975. Epub 2013 Mar. 10.1158/0008-5472.CAN-12-4140.
14. Hodgkinson C.L., Morrow C.J., Li Y., Metcalf R.L., Rothwell D.G., Trapani F., et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat. Med. 2014, 20(8):897-903. Epub 2014 Jun 1. 10.1038/nm.3600.
15. Hou J.M., Krebs M.G., Lancashire L., Sloane R., Backen A., Swain R.K., et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 2012, 30(5):525-532. Epub 2012 Jan 17. 10.1200/JCO.2010.33.3716.
16. Kidess E., Jeffrey S.S. Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?. Genome Med. 2013, 5(8):70.
17. Krebs M.G., Metcalf R.L., Carter L., Brady G., Blackhall F.H., Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat. Rev. Clin. Oncol. 2014, 11(3):129-144. Epub 2014 Jan 21. 10.1038/nrclinonc.2013.253.
18. Leary R.J., Sausen M., Kinde I., Papadopoulos N., Carpten J.D., Craig D., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl Med. 2012, 4(162). 162ra154. 10.1126/scitranslmed.3004742.
19. Luke J.J., Oxnard G.R., Paweletz C.P., Camidge D.R., Heymach J.V., Solit D.B., et al. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J. Natl. Cancer Inst. 2014, 106(8).
20. Mohan S., Heitzer E., Ulz P., Lafer I., Lax S., Auer M., et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. Plos Genet. 2014, 10(3):e1004271. eCollection 2014. 10.1371/journal.pgen.1004271.
21. Murtaza M., Dawson S.J., Tsui D.W., Gale D., Forshew T., Piskorz A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497(7447):108-112. Epub 2013 Apr 7. 10.1038/nature12065.
22. Norton S.E., Luna K.K., Lechner J.M., Qin J., Fernando M.R. A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device. J. Clin. Lab Anal. 2013, 27(4):305-311. 10.1002/jcla.21603.
23. Peifer M., Fernández-Cuesta L., Sos M.L., George J., Seidel D., Kasper L.H., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 2012, 44(10):1104-1110. Epub 2012 Sep. 2. 10.1038/ng.2396.
24. Ramsköld D., Luo S., Wang Y.C., Li R., Deng Q., Faridani O.R., et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat. Biotechnol. 2012, 30(8):777-782.
25. Rothwell D.G., Li Y., Ayub M., Tate C., Newton G., Hey Y., et al. Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells. BMC Genomics 2014, 15:1129. 10.1186/1471-2164-15-1129.
26. Rudin C.M., Durinck S., Stawiski E.W., Poirier J.T., Modrusan Z., Shames D.S., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 2012, 44(10):1111-1116. Epub 2012 Sep. 2. 10.1038/ng.2405.
27. Toyokawa G., Takenoyama M., Taguchi K., Toyozawa R., Inamasu E., Kojo M., et al. An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. Lung Cancer 2013, 81(3):487-490.